Navigation Links
Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
Date:11/5/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.

On Wednesday, Nov. 13 at 3:20 p.m., Philip Wills, Ph.D., Chief Commercial Officer, Paragon Gene Therapy (part of Catalent Biologics) will present “Capacity Crunch? The Future of Manufacturing Within Cell & Gene Therapy” as part of the manufacturing track. Dr. Wills’ presentation will highlight the challenges that the gene therapy sector faces in scale-up and manufacturing, driven by the rising numbers of clinical trials and FDA approvals, coupled with low product yields and rising treatment costs. These factors have led to an increased demand for process expertise and manufacturing capacity, and Dr. Wills will address the capacity limitations and discuss the future of cell and gene therapy manufacturing.

Also, on Wednesday, at 2:20 p.m., Stephen Tindal, Director, Science & Technology and Gavin Yates, Program Director, Clinical Supply Services and Drug Product Technologies Integrations, will discuss the benefits of contracting with a single, integrated provider in their presentation, “Next Exit, Success: Get from Concept to Clinic Faster on the Product Development Superhighway.” In the presentation, Mr. Tindal and Mr. Yates will highlight opportunities to streamline and shorten product development timelines.

Dr. Wills has almost two decades of contract manufacturing experience, primarily focused in viral vectors and other complex biologics. He joined Paragon in 2002 where he has since held positions of increasing scope and responsibility, including as Principal Scientist and Vice President of Business Development. He received a bachelor’s degree in chemistry from John Hopkins University, Baltimore, Maryland, and a doctorate in pharmacology from University of Maryland Medical School, Maryland.

Mr. Tindal has worked in softgel R&D for more than 30 years and has broad expertise in this technology. He specializes in root cause investigation, technology innovation, gelatin innovation, and plays a key role in customer liaison and supporting business development. Mr. Tindal holds a bachelor’s degree in chemistry and analytical science from Loughborough University, U.K.

Mr. Yates has more than 15 years’ experience in the pharmaceutical industry. His areas of expertise include project management, packaging and labeling, operational activity, supply chain management and key performance indicator (KPI) analysis. He received his bachelor’s degree in biological sciences from University of Birmingham, U.K.

For more information, visit https://www.catalent.com/index.php/news-events/events/World-Orphan-Drug-Congress-Europe.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard@nepr.agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_discuss_the_future_of_cell_and_gene_therapy_manufacturing_at_world_orphan_drug_congress_europe/prweb16695271.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
2. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
3. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
4. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
5. Catalent Receives P&G External Business Partner of the Year Award
6. Biopharma Leaders to Discuss and Share Insights on the Regional Biopharma Ecosystem at LeadingBiotech’s NY/NJ CEO Conference
7. Biopharma Leaders Convene to Discuss Topics in Biotech, Healthcare and Innovation at LeadingBiotech’s Inaugural South CEO Conference
8. Greenberg Traurig Hosts Boston Healthcare Drinks and Discussion on China Biopharma Industry
9. Cell Signaling Technology Discusses Challenges and Opportunities of Post-translational Modifications and Data-Independent Acquisitions in Educational Webinar
10. DiaSorin Furthers the Discussion on HDV, the Most Severe Form of Viral Hepatitis, in Educational Webinar
11. STEM Initiatives in Grade School are Discussed on "On Demand" with Rob Lowe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... December 04, 2019 , ... Cartessa Aesthetics ... Advanced Plasma Technology for U.S. dermatologists, plastic surgeons and licensed aesthetic providers. ... to employ LF technology – low frequency plus a patented wavelength and power ...
(Date:11/27/2019)... ... November 26, 2019 , ... Smile Glen Ellyn dentists, Drs. ... Invisalign® treatment. Invisalign orthodontics uses a series of clear, virtually invisible ... known as malocclusion, present both functional and cosmetic concerns. Functionally, crooked teeth ...
(Date:11/22/2019)... BUFFALO, N.Y. (PRWEB) , ... November 21, 2019 ... ... immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step ... and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell ...
Breaking Biology News(10 mins):
(Date:1/7/2020)... ... January 06, 2020 , ... ... World at The Fletcher School at Tufts University, is pleased to announce that ... grant will be administered by Tufts University, and will help to expand the ...
(Date:12/31/2019)... ... December 31, 2019 , ... At this year's SLAS conference, ... be broadly focused on 3D cell culture , advanced imaging and ... culture assays for assessing steatosis , inflammation and fibrosis as well ...
(Date:12/23/2019)... ... December 23, 2019 , ... Leak ... the Pharmaceutical, Biotechnology and Medical Device Industries, is excited to announce that it ... Drug Association (PDA) Container Closure Integrity Testing Basic Training Course . Held in ...
(Date:12/14/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... December ... ... the world’s premier manufacturer of custom built, helium-based leak testing instruments for the ... second major product launch of 2019. The new LDA LT80 (LOW TEMPERATURE -80C) ...
Breaking Biology Technology: